Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Waldenstrom Macroglobulinemia 1Solid Tumors 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 23Cisplatin 19Nivolumab 8Gemcitabine 7Ipilimumab 6Carboplatin 6pembrolizumab 4Bevacizumab 4tazemetostat 3durvalumab 3Fluorouracil 3Drug Therapy 3spartalizumab 2olaparib 2niraparib 2budigalimab 2belinostat 2anetumab ravtansine 2amatuximab 2Vinorelbine 2Radiotherapy, Intensity-Modulated 2Paclitaxel 2PM 01183 2Oxaliplatin 2Imatinib Mesylate 2Everolimus 2Erlotinib Hydrochloride 2Doxorubicin 2Cyclophosphamide 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mesothelioma × CB-839 × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡